Paper Information

Title: 

A RECOMBINANT GRA2 PROTEIN OF TOXOPLASMA GONDII PARTIALLY PROTECTS AGAINST BRAIN CYSTS PRODUCTION IN C57BL/6 MICE

Type: PAPER
Author(s): GOLKAR M.,BABAEI JALAL*,AZADMANESH K.,PIAZAK N.,ASMAR MAHDI
 
 *MOLECULAR PARASITOLOGY LABORATORY, PASTEUR INSTITUTE OF IRAN, 69 PASTEUR AVE., TEHRAN 1316943551, IRAN
 
Name of Seminar: BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY
Type of Seminar:  CONGRESS
Sponsor:  IRAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES
Date:  2007Volume 6
 
 
Abstract: 

 Introduction: Toxoplasmosis, a disease caused by the parasite Toxoplasma gondii, is considered as one of the health problems worldwide. Drug therapy can control the Toxoplasma infection, but it cannot eradicate Toxoplasma gondii nor prevent the reactivation of the infection. Vaccination seems to be the most efficacious method to prevent and control the infection. The dense granule antigen 2 (GRA2) has been introduced as a promising vaccine candidate in animal models.
Materials and Methods: C57BL/6 mice were immunized with either a recombinant GRA2 (rGRA2) protein, formulated in monophosphoryl lipid (MPL) adjuvant, or a DNA vaccine encoding GRA2 protein. Mice were challenged with cysts of T. gondii and brain cysts were counted one month later.
Results: Mice immunized with rGRA2 decreased brain cyst production by 52.6 % (p<0.03) as compared to the control group. In contrast, DNA vaccination with GRA2 failed to protect against the infection following the challenge with cysts of Tehran strain. A significant decrease in the cyst number of reGRA2 protein immunized group (52.6%) compared to control group was observed and indicated the considerable protection induced by reGRA2 protein. The results showed that immunization with pcDNA3.1-GRA2 construct did not induce considerable protection against infection.
Discussion: The results showed that vaccination of C57BL/6 mice with the rGRA2 is more protective against chronic T. gondii infection than a GRA2 DNA vaccine. The use of other adjutants and/or combination use of DNA and protein and DNA might improve the protective efficacy of rGRA2 protein.

 
Keyword(s): DNA VACCINE, RGRA2, TOXOPLASMA GONDII, CHRONIC INFECTION
 
Yearly Visit 27   tarjomyar
 
Latest on Blog
Enter SID Blog